Coya Therapeutics (COYA) Convertible Debt (2022)
Coya Therapeutics (COYA) reported Convertible Debt of $13.0 million for Q4 2022.
Coya Therapeutics (COYA) Convertible Debt (2022) Analysis & Trends
Coya Therapeutics (COYA) has 1 years of Convertible Debt data on file, last reported at $13.0 million in Q4 2022.
- For the quarter ending Q4 2022, Convertible Debt changed N/A year-over-year to $13.0 million; the trailing twelve-month figure through Dec 2022 stood at $13.0 million (changed N/A YoY), and the FY2022 full-year result was $13.0 million, changed N/A from the prior year.
- Convertible Debt was little changed at $13.0 million in Q4 2022.
- In the past five years, Convertible Debt ranged from a high of $13.0 million in Q4 2022 to a low of $13.0 million in Q4 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,102.16 Bn | 67,101.87 Bn | - |
| 2 | Nanobiotix | 1,913.50 Bn | 1,913.44 Bn | - |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - |
| 4 | BeOne Medicines | 473.74 Bn | 468.95 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 122.07 Bn | 114.82 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 70.00 Bn | 61.24 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.34 Bn | 62.34 Bn | - |
| 8 | Argenx Se | 55.96 Bn | 50.77 Bn | 1.41 Bn |
| 9 | Alnylam Pharmaceuticals | 37.49 Bn | 34.48 Bn | 959.66 Mn |
| 10 | Coya Therapeutics | 98.05 Mn | 47.33 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2022 | 12.97 Mn |